- Home
- BZUN vs ABOS Comparison
BZUN vs ABOS Comparison
Compare BZUN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- ABOS
- Stock Information
- Founded
- BZUN 2007
- ABOS 1996
- Country
- BZUN China
- ABOS United States
- Employees
- BZUN N/A
- ABOS N/A
- Industry
- BZUN Catalog/Specialty Distribution
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- ABOS Health Care
- Exchange
- BZUN Nasdaq
- ABOS Nasdaq
- Market Cap
- BZUN 188.7M
- ABOS 99.1M
- IPO Year
- BZUN N/A
- ABOS 2021
- Fundamental
- Price
- BZUN $2.74
- ABOS $1.56
- Analyst Decision
- BZUN Strong Buy
- ABOS Strong Buy
- Analyst Count
- BZUN 3
- ABOS 3
- Target Price
- BZUN $3.20
- ABOS $9.33
- AVG Volume (30 Days)
- BZUN 874.6K
- ABOS 379.4K
- Earning Date
- BZUN 11-21-2024
- ABOS 11-12-2024
- Dividend Yield
- BZUN N/A
- ABOS N/A
- EPS Growth
- BZUN N/A
- ABOS N/A
- EPS
- BZUN N/A
- ABOS N/A
- Revenue
- BZUN $1,312,737,613.00
- ABOS N/A
- Revenue This Year
- BZUN $8.16
- ABOS N/A
- Revenue Next Year
- BZUN $4.71
- ABOS N/A
- P/E Ratio
- BZUN N/A
- ABOS N/A
- Revenue Growth
- BZUN 7.26
- ABOS N/A
- 52 Week Low
- BZUN $1.90
- ABOS $1.54
- 52 Week High
- BZUN $4.38
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- BZUN 46.21
- ABOS 30.29
- Support Level
- BZUN $2.67
- ABOS $1.69
- Resistance Level
- BZUN $3.09
- ABOS $1.88
- Average True Range (ATR)
- BZUN 0.17
- ABOS 0.13
- MACD
- BZUN -0.03
- ABOS -0.00
- Stochastic Oscillator
- BZUN 14.08
- ABOS 4.88
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.